10.05.2022 - -Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022- -FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold- -Clinical .